Head of Clinical Trials, @hospitalmoinhos 🇧🇷 | Professor, PG Cardiology, @ufrgsnoticias 🇧🇷 | Fellowship, @TIMIStudyGroup 🇺🇸 | Lipids, Trials, Cardiology
Joined May 2016
- Tweets 1,170
- Following 849
- Followers 1,885
- Likes 3,705
330 Photos and videos
Pinned Tweet
29 Aug 2025
Today, I had the honor to present PhysioSync-HF as a Late-Breaking Clinical Trial at #ESCCongress.
Key message: In HFrEF and LBBB, conduction system pacing was *inferior* to biventricular pacing for a composite of death, HF events, and LVEF change at 12 months.
6
35
156
23,653
André Zimerman retweeted
In patients with severe hypertriglyceridemia, olezarsen reduced triglycerides and risk for acute pancreatitis events compared with placebo at 12 months.
#EAS2026 @EASCongress @AndreZimerman @ionispharma
vist.ly/57dbr
3
2
323
May 28
Terrific thread, thank you for highlighting @FedericaFogacci!
When TG reach ≥10 mmol/L, the question is no longer only lipid lowering. It is #pancreatitis prevention.
At #EASCongress2026, @AndreZimerman presents CORE TIMI 72a and CORE2 TIMI 72b data on #olezarsen in patients with TG ≥10 mmol/L and acute pancreatitis risk @TIMIStudyGroup
2
3
519
André Zimerman retweeted
#EASCongress2026
@AndreZimerman presents a late breaker clinical trial exploring olezarsen for acute pancreatitins in pts w/triglycerides>10 mMol/L. As can be seen, a stark difference in favour of Olezarsen in this cohort highly exposed to risk of acute pancreatitis.
6
17
697
May 21
One of my favorite projects at TIMI.
While exploratory, our findings support the concept that lowering LDL-C through PCSK9i may prevent the formation and progression of arterial aneurysms, including AAA.
Now in @CircAHA
@PrakritiGaba @marstonMD @BrianBergmark @TIMIStudyGroup
May 21
#Research letter: Earlier initiation of the PCSK9 inhibitor Evolocumab reduced the risk of arterial aneurysm events compared with delayed initiation in an analysis of the FOURIER trial ahajrnls.org/3PCdvbV
1
3
12
3,684
André Zimerman retweeted
We are deeply saddened to have lost our founding chairman and the father of modern academic cardiology, Dr. Eugene Braunwald, who founded the TIMI Study Group in 1984, and with that vision profoundly shaped the practice of cardiovascular medicine across the world.
4
71
226
8,709
André Zimerman retweeted
Mar 30
#SimPub #ACC26 In CCTA substudy of Essence-TIMI 73b (RCT of olezarsen vs. placebo in patients with hypertriglyceridemia), no difference in non calcified, coronary plaque volu... @marstonMD @maciejbanach @AndreZimerman @michael_t_lu @BrianBergmark @BudoffMd ahajrnls.org/4m4ZwHK
2
13
41
82,012
André Zimerman retweeted
Mar 11
In patients with #HeartFailure and #LBBB, conduction system pacing (#CSP) was inferior to biventricular pacing (#BiVP) for a composite of death, heart failure events, and LVEF change at 12 months.
ja.ma/3PgczJP
4
47
150
14,060
Mar 13
Proud to see PhysioSync-HF published in @JAMACardio.
In patients with HFrEF and LBBB, conduction system pacing was inferior to biventricular pacing for a composite of death, HF events, and LVEF change at 12 months.
Let us know your thoughts: jamanetwork.com/journals/jam…
2
3
22
1,022
Mar 13
Please check out the accompanying editorial, which nicely contextualizes the apparently opposing findings from PhysioSync-HF and HeartSync-LBBP: jamanetwork.com/journals/jam…
3
202
André Zimerman retweeted
22 Dec 2025
Small-interfering RNA olpasiran reduced lipoprotein(a)–apolipoprotein B particles by >95% with minimal rise in non–Lp(a)-apoB, lowering total apoB concentration in patients with cardiovascular disease. ja.ma/49iZoiR
1
14
35
4,126
24 Nov 2025
How do Lp(a)-lowering agents affect atherogenic lipoproteins more broadly?
In our @JAMACardio study, we show that olpasiran, an siRNA targeting apo(a), reduced Lp(a) in >95% without increasing non-Lp(a) particles.
apoB was ultimately reduced by ~18%.
@TIMIStudyGroup
1
3
11
2,261
24 Nov 2025
These findings suggest that, with olpasiran, apoB particles normally destined to form Lp(a) are either not secreted into circulation or more efficiently cleared, providing context for interpreting results of ongoing trials of Lp(a)-lowering agents.
Link:
jamanetwork.com/journals/jam…
2
134
André Zimerman retweeted
5 Nov 2025
Small-interfering RNA olpasiran reduced lipoprotein(a)–apolipoprotein B particles by >95% with minimal rise in non–Lp(a)-apoB, lowering total apoB concentration in patients with cardiovascular disease.
ja.ma/4qqkClo
ALT Bar graph titled 'Effect of Olpasiran on Apolipoprotein B'. It shows Non-Lp(a)-apoB and Lp(a)-apoB concentrations at baseline and week 36 for placebo and Olpasiran at 10mg/12 wk, 75mg/12 wk, and 225mg/12 wk.
15
44
4,806
André Zimerman retweeted
5 Nov 2025
Why does interference of apo(a) synthesis with #olpasiran also lead to a net reduction in apoB particles? Read more online now @JAMACardio @DrM_ODonoghue @AndreZimerman
jamanetwork.com/journals/jam…
3
9
1,074
29 Oct 2025
I had a great discussion with @DrJMarine on the PhysioSync-HF trial, our (unexpected) findings, and what they mean for the field.
Check out our @ACCinTouch podcast episode on Spotify:
open.spotify.com/episode/1fl…
29 Oct 2025
The PhysioSync-HF trial investigates conduction system pacing as a potentially more effective & affordable alternative to traditional cardiac resynchronization therapy.
Tune into #ACCEL Lite episode for more insights ➡️ bit.ly/4qxh6pp
@DrJMarine @AndreZimerman #CardioX
5
992
André Zimerman retweeted
24 Oct 2025
Greatly enjoyed speaking with @AndreZimerman about his trial results reported at ESC.25. Surprisingly, CSP inferior to conventional CRT in this HFrEF population. Listen to learn more! @ACCinTouch @a_l_bailey
ACCEL Lite: PhysioSync-HF: Conduction System vs. Biventricular Pacing in Cardiac Resynchronization in HFrEF - American College of Cardiology acc.org/Latest-in-Cardiology…
1
4
752
André Zimerman retweeted
Our webinar on '25 update of European lipid guidelines has just been held, w/a very enriching discussion led by myself and @FabianaRached following presentations of @AL_Catapano., @ProfKausikRay, and @AndreZimerman Thanks to all participants. Soon online at @society_eas website.
3
11
759
André Zimerman retweeted
👇👇👇 Thursday, October 23th at noon, Brasilia time. We will have 3 presentations, respectively by @AL_Catapano, @ProfKausikRay on combination #LLT and @AndreZimerman on #Lpa. Subtitles in portuguese. Presentations will be followed by a Q & A session. #cardiotwitter
20 Oct 2025
The Lipid Clinic Network local webinars on the Focused Update are tailored sessions designed to support national dissemination of the new guidance, adapt it to local clinical priorities, and foster collaboration between international experts and national networks.
Each webinar is co-developed with local experts to address country-specific perspectives and challenges, ensuring a practical translation of the new ESC/EAS recommendations.
The first webinar in the series will take place this Thursday in Brazil. Register now if this is your region: eas.to/LCNWebBrazil @pabeda1 @ProfKausikRay @KatiOorni
1
2
8
1,383
André Zimerman retweeted
10 Sep 2025
🚨 BREAKING: ESC 2025 Spotlight!
#HRStv host @melchami99, sits down with @AndreZimerman, and @Davilandre to break down the PhysioSync-HF trial, presented at ESC Congress 2025 in Madrid. This multicenter study compares conduction system pacing vs biventricular resynchronization in patients with heart failure and left bundle branch block.
See the full interview here #EPeeps ➡️ bit.ly/41PF2d3
#ESC2025 #HeartFailure #Cardiology #EP
4
8
1,072
André Zimerman retweeted
5 Sep 2025
Painstaking , careful work from everyone involved. So much effort from the patients, ARO, CRO, and sponsor to get here.
It gives a sense of pride being part of the team.
Can’t wait for the severe HTG population data, where there will be more immediate impact to patients’ lives.
3 Sep 2025
In patients with TGs >150 mg/dL, apoC-III inhibitor olezarsen reduced TGs by *60%*.
Also lower: apoB (↓15%), non-HDL-C (↓22%), and remnant chol (↓68%).
The CTA analysis will help clarify the potential CV benefit.
Proud to be a part of this team. Now published in the @NEJM.
1
11
974